[The usefulness of UFT administration in colorectal cancer with emphasis on postoperative administration (Part 3)].
To investigate the usefulness of the postoperative administration of UFT for colorectal cancer, 109 patients with a history of colorectal cancers from Nagasaki University First Department of Surgery and seven affiliated facilities were selected as subjects. After administering UFT 400 mg/day to both A and B groups one week prior to surgery, MMC 20 mg during surgery and 10 mg on the first day after surgery, the groups were divided into an A group, not administered UFT, and B group, administered UFT 400 mg/day. In addition, both groups were administered MMC 6 mg/m2 six times a month starting the first month after surgery. Although the A group consisted of 54 patients and the B group 55, 52 patients of the A group and 46 patient of the B group, for a total of 98, qualified as subjects for this investigation, and the following results were obtained. 1) Postoperative administration of UFT was useful in prolonging the survival period in non-curable resection cases, in Dukes C group cases, and in cases that exhibited a nuclear DNA aneuploid pattern. It was especially useful in improving the postoperative survival rate from the second year on. 2) When recurrent cases were examined, it was found to be effective in preventing remote metastasis in those cases administered UFT postoperatively. 3) There were no serious adverse effects and the majority of those that did occur were anorexia and diarrhea.
Tomita
M
M
First Dept. of Surgery, Nagasaki University School of Medicine.
Ishikawa
H
H
Nakagoe
T
T
Shimizu
T
T
Hirano
T
T
Eida
K
K
Ishii
T
T
Tobinaga
K
K
Kotake
Y
Y
Nogawa
T
T
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols; D015179:Colorectal Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology / Q000601:surgery; D003131:Combined Modality Therapy; D005260:Female; D006801:Humans; D008207:Lymphatic Metastasis; D008297:Male; D008875:Middle Aged; D016685:Mitomycin / Q000627:therapeutic use; D009362:Neoplasm Metastasis; D009360:Neoplastic Cells, Circulating; D011184:Postoperative Period; D015996:Survival Rate; D005641:Tegafur / Q000627:therapeutic use; D014498:Uracil / Q000627:therapeutic use
D000970:Antineoplastic Agents; D005641:Tegafur; D016685:Mitomycin; D014498:Uracil